MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers

BET inhibitors exhibit broad activity in cancer models, making predictive biomarkers challenging to define. Here we investigate the biomarkers of activity of the clinical BET inhibitor GSK525762 (I-BET; I-BET762) across cancer cell lines and demonstrate that KRAS mutations are novel resistance bioma...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncogenesis
Main Authors: Wyce, Anastasia, Matteo, Jeanne J., Foley, Shawn W., Felitsky, Daniel J., Rajapurkar, Satyajit R., Zhang, Xi-Ping, Musso, Melissa C., Korenchuk, Susan, Karpinich, Natalie O., Keenan, Kathryn M., Stern, Melissa, Mathew, Lijoy K., McHugh, Charles F., McCabe, Michael T., Tummino, Peter J., Kruger, Ryan G., Carpenter, Christopher, Barbash, Olena
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5908790/
https://ncbi.nlm.nih.gov/pubmed/29674704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0043-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares